An interventional study of Entre Herman@s and Vaccines for Health in HIV Infections, sponsored by Charles Drew University of Medicine and Science. Completed at 1 site in United States. Open to participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Charles Drew University of Medicine and Science · Not applicable, Interventional, and Prevention
Among 2,802 studies in HIV Infections with a site in United States — 83 open to participants now, 140 under way, 11 of them phase 3. HIV Infections · United States.
Among the 2,802 studies in HIV Infections with a site in United States, this one is the 440th largest by enrollment of the 2,150 interventional ones, is one of 54 that started in 2023, is one of 718 with no phase, and was the 2,679th registered.
4,734 studies on the registry are indexed under HIV Infections; 244 are open to participants now.
This study's enrollment of 288 is above the median of 80 across 3,489 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →83 of the 2,802 studies in HIV Infections with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 158 HIV Infections studies recruiting now, 104 (66%) set no upper age limit and 41 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 39 Years · all sexes · healthy volunteers too.
The full table on the hub →2,802 studies; the count open now beside each. This study's row is marked.
First in 1984; this study’s year is marked. 54 started in 2023.
Median enrollment 60 across the 2,150 interventional studies, 135 across the 350 observational. Of the 2,530 that completed or were terminated, 558 (22%) have results posted.
857 of 2,802 have an industry lead sponsor. The 10 most frequent:
Charles Drew University of Medicine and Science is the lead sponsor of 43 studies on the registry; 1 is open to participants now.
Charles Drew University of Medicine and Science has 2 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
53 of the studies in HIV Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550804Phase 3University of Illinois at ChicagoTesting a Real-time Electronic Antiretroviral Adherence Monitoring Intervention | 2027-03 |
| NCT04833829Emory UniversityCross-disciplinary HIV Integrated Mental Health Support Intervention | 2026-11 |
| NCT05398185Columbia UniversityWiseApp for Spanish Speakers Living With HIV | 2026-11-01 |
| NCT05833074Hunter College of City University of New YorkEvaluating the Efficacy of Annual CHTC Retesting Among Male Couples at High Risk of HIV Infection | 2026-11-01 |
| NCT04577313University of ConnecticutHIV Treatment Adherence Dose Determination Trial | 2026-11-30 |
Among the 2,802 studies in HIV Infections with a site in United States, from their registry updates:
This is a randomized controlled trial with an attention placebo control group. The goal of this study is to decrease HIV incidence in Latino men who have sex with men by engaging their siblings in PrEP-use promotion. In the intervention arm, siblings will be trained to engage their gay brother in PrEP conversations. In the control arm, siblings will be trained to engage their gay brother in conversations about vaccines to prevent COVID, Hepatitis A/B, or MPOX.
Inclusion Criteria: Latino Men Who Have Sex with Men
Exclusion Criteria: Latino Men Who Have Sex with Men
Inclusion Criteria: Siblings
Exclusion Criteria: Siblings
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Entre Herman@s
Behavioral: Vaccines for Health
The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a PrEP Conversation followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a Health Conversation about vaccines for COVID, Hep A/B, or MPOX, followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
Number of participants that start using PrEP
This measures how many participants in the experiment group started taking PrEP (baseline = 0 participants). Tool: Pictures. Participants will submit a picture of their pill bottle to report PrEP use.
Time frame: 90 days
Number of participants that get vaccinated
This measures whether participants in the control group decided to get vaccinated for COVID, Hep A/B, or MPOX. Tool: Pictures. Participants will submit a picture of their proof-of-vaccination card to report vaccination status.
Time frame: 90 days
Number of participants who increase their willingness to use PrEP
This measures whether participants progress along the stages of change (e.g., pre-contemplation, contemplation, action) in their willingness to try PrEP if it were available to them. Tool: Stages of Change questionnaire administered at baseline and 90 days.
Time frame: 90 days
Number of participants who increase their willingness to get vaccinated
This measures whether participants progress along the stages of change (e.g., pre-contemplation, contemplation, action) in their willingness to get vaccinated against COVID, Hep A/B, or MPOX if it were available to them. Tool: Stages of Change questionnaire administered at baseline and 90 days.
Time frame: 90 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2023 to primary completion in Feb 2025, 21 months.
Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's 21 months is below that.
Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charles Drew University of Medicine and Science